Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer

BACKGROUND: Docetaxel–prednisone (DP) is an approved therapy for metastatic castration-resistant prostate cancer (mCRPC). Orteronel (TAK-700) is an investigational, selective, non-steroidal inhibitor of 17,20-lyase, a key enzyme in androgenic hormone production. This phase 1/2 study evaluated ortero...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Invest New Drugs
मुख्य लेखकों: Petrylak, Daniel P., Gandhi, Jitendra G., Clark, William R., Heath, Elisabeth, Lin, Jianqing, Oh, William K., Agus, David B., Carthon, Bradley, Moran, Susan, Kong, Ning, Suri, Ajit, Bargfrede, Michael, Liu, Glenn
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4390470/
https://ncbi.nlm.nih.gov/pubmed/25556680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0199-x
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन